Reports

Drug name	NICE TAs	Comments
Trastuzumab deruxtecan (Enhertu®)	TA704 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
Trastuzumab emtansine	TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Trastuzumab infusion	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer TA107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Funding approval should be sought prior to initiation
Trifluridine-tipiracil (Lonsurf®)	NICE TA 1008 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Trimovate cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Moderate potency.
Upadacitinib (Rinvoq®)	TA665 - Upadacitinib for treating severe rheumatoid arthritis TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA829 - Upadacitinib for treating active ankylosing spondylitis TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis
Upadacitinib (Rinvoq®)#1.5	TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis
Ustekinumab	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis	Hospital use only
Ustekinumab (Stelara®)	TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment TA456 - Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab#13.5	TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports